Pregnancy Risks With First Trimester GLP-1 Continuation - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Pregnancy Risks With First Trimester GLP-1 Continuation

Claims-based target trial emulation found no clear association between continued GLP-1 receptor agonist use in early pregnancy and nonlive birth, fetal growth abnormalities, or major congenital malformations.

  • By

  • Andrea Surnit

  • June 17, 2026

  • 3 min

Share

  • 1

    Continuation of GLP-1 receptor agonists in the first trimester does not show a clear increase in nonlive birth or major congenital malformations.

  • 2

    The study analyzed 3,572 pregnancies, comparing outcomes between those who continued GLP-1 treatment and those who did not.

  • 3

    The adjusted risk ratio for nonlive birth was 1.09, indicating no significant difference in risk between treatment groups.

  • 4

    Elective termination rates were higher among patients who continued GLP-1 treatment, potentially due to various influencing factors.

  • 5

    The study's observational design has limitations, including potential residual confounding and imprecise estimates for some outcomes.

Original Source(s)

Pregnancy Risks With First Trimester GLP-1 Continuation

  • by Andrea Surnit

  • June 17, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Integrated model of Student Standardized Patients and peer assessment enhances SOAP note proficiency in obstetrics and gynecology residency